

Carbon Reduction Plan

Supplier name: TriOn Pharma Limited

Publication date: 04/07/2025

Commitment to achieving Net Zero

TriOn Pharma Limited is committed to achieving Net Zero emissions by 2045.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2022/23

Additional Details relating to the Baseline Emissions calculations

Due to the limited scope of reporting in previous years, 2022/23 will be taken as the baseline year by which to measure progress towards TriOn Pharma Limited's Net Zero commitments. The conversion factors used are for location based reporting.

The scope 1 and 2 data are from supplier sourced data across 2 sites and has a high data confidence level.

The scope 3 data have been generated using a mix of sources:

- Upstream Transportation & Distribution emission calculations have a high level of confidence for circa 50% of the data from supplier information, loads and mileages with the remainder of medium confidence using delivery mileage and load assumptions.
- Waste Generated from Operations figures have been calculated from supplier data so have a high level of confidence.
- Business Travel has been calculated from spend data by type of travel, giving a medium confidence level.
- Employee Commuting has been calculated from an Employee Commuting Survey and has a medium level of confidence
- Downstream Transportation & Distribution calculations use EEIO spend analysis giving a medium level of confidence.

All data has been compiled with reference to and using data from:

- <https://ghgprotocol.org/corporate-standard>
- <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting> (2025 data set)

In 2023-25 the aim is to complete the following actions to improve Scope 3 data confidence going forward:

Scope 3 category	2023-25 actions to improve data accuracy
4. Upstream transportation & distribution	Engage with manufacturers to provide data; capture by accounts on invoicing or develop other effective capture mechanism. The timetable will be defined based on manufacturer feedback.
5. Waste generated in operations	High confidence level already.
6. Business travel	Adapt expenses process to capture vehicle mode and mileage routinely.
7. Employee commuting	Develop HR systems to link commuting data with attendance.
9. Downstream transportation and distribution	Engage with suppliers to provide data; adapt accounting processes to capture on invoicing or develop other effective capture mechanism.

The figures and information used in calculations have been provided as accurate to the best of our knowledge and as far as practicable we have assumed that figures are representative of our operations. We will undertake a continual process of improving our data quality. In the case that we identify any material changes, we may recalculate the baseline data in the future.

Baseline year emissions: April 2022 to March 2023


EMISSIONS	TOTAL (tCO₂e)														
Scope 1	61.8														
Scope 2	70.2														
Scope 3 (Included Sources)	1225.7 <table border="1"> <thead> <tr> <th>Scope 3 category breakdown</th><th>tCO₂e</th></tr> </thead> <tbody> <tr> <td>4. Upstream transportation and distribution</td><td>129.0</td></tr> <tr> <td>5. Waste generated in operations</td><td>1.3</td></tr> <tr> <td>6. Business travel</td><td>43.2</td></tr> <tr> <td>7. Employee commuting</td><td>113.2</td></tr> <tr> <td>9. Downstream transportation and distribution</td><td>939.0</td></tr> <tr> <td>Total Reduction Plan Scope 3</td><td>1,225.7</td></tr> </tbody> </table>	Scope 3 category breakdown	tCO₂e	4. Upstream transportation and distribution	129.0	5. Waste generated in operations	1.3	6. Business travel	43.2	7. Employee commuting	113.2	9. Downstream transportation and distribution	939.0	Total Reduction Plan Scope 3	1,225.7
Scope 3 category breakdown	tCO₂e														
4. Upstream transportation and distribution	129.0														
5. Waste generated in operations	1.3														
6. Business travel	43.2														
7. Employee commuting	113.2														
9. Downstream transportation and distribution	939.0														
Total Reduction Plan Scope 3	1,225.7														
Total Emissions	1,357.7														

Current Emissions Reporting

Reporting Year: April 2024 to March 2025		
EMISSIONS	TOTAL (tCO ₂ e)	
Scope 1	59.8	
Scope 2	66.2	
Scope 3 (Included Sources)	1163.1	
	<i>Scope 3 category breakdown</i>	<i>tCO₂e</i>
	4. Upstream transportation and distribution	122.0
	5. Waste generated in operations	0.8
	6. Business travel	40.1
	7. Employee commuting	100.2
	9. Downstream transportation and distribution	900.0
	<i>Total Reduction Plan Scope 3</i>	<i>1,163.1</i>
Total Emissions	1,289.1	

Emissions reduction targets

In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets.



Note: Unavoidable emissions by 2045 will be offset via an accredited scheme.

We project that carbon emissions will decrease over the next five (5) years to 873 tCO₂e by 2027/28. This is a reduction of 35%.

As this is our baseline year there is no progress to be tracked yet against our targets, however the reduction path is plotted below.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

Since the 2022/23 baseline year, TriOn Pharma Limited has implemented a range of carbon reduction measures, resulting in a reduction in total emissions from 1,357.7 tCO₂e to 1,289.1 tCO₂e during the period April 2024 to March 2025. This represents a total reduction of 68.6 tCO₂e, equivalent to a 5.05% decrease in emissions compared to the baseline.

As this is the second full reporting cycle following the baseline year, the reductions achieved are now measurable and demonstrate our early progress toward Net Zero.

- Started transitioning fleet to electric vehicles (36% EV, and 36% hybrid in March 2023)
- All space and water heating are now thermostat and timer controlled
- Low energy lighting installed on all buildings occupied by TriOn Pharma Limited
- 16m² solar panels installed at our iO Centre, Sutton site
- Encouraging remote working and virtual meetings to reduce business travel

In the future we hope to implement further measures such as:

Scope 1:

- Complete the transition of company owned fleet from internal combustion engines to electric and other low carbon alternatives in line with the developments in the car market.

Scope 2:

- Investigate and where practicable install additional solar panels to increase self-generated renewable energy
- Switch all electricity supplies to REGO certified sources

Scope 3:

- Work with logistics partners to reduce upstream and downstream transportation & distribution emissions.
- Continue digitisation and innovation to optimise batch sizes and delivery schedules to get the best mix of customer experience and carbon efficiency.

The future savings have yet to be quantified. As more accurate granular data becomes available and our strategy evolves, we will quantify the savings targets.

Declaration and Sign-off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of TriOn Pharma Ltd:



Name: Mr. V K Patel

Position: Commercial Director

Date: 04/07/2025

TriOn Pharma Limited:

TriOn Pharma Limited is the UK based leading specialist provider of Pharmaceuticals, Nutraceuticals and medical devices in the field of respiratory, urology, ophthalmology, dermatology and urogynecology.

For more information please contact:
TriOn Pharma Limited
Unit 7 Kimpton Link Business Park
40 Kimpton Road, Sutton SM3 9QP
UK

¹<https://ghgprotocol.org/corporate-standard> ²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting> ³<https://ghgprotocol.org/standards/scope-3-standard>

Version control

Version	Change	Author	Date
2.1	Document created.	Jacquie R / D Rana	16/05/2025
2.2	Initial draft sent to TriOn Pharma for review.	Jacquie R / D Rana	19/05/2025
2.3	Draft reviewed with TriOn Pharma SMT.	Rosco Smith	03/06/2025
3.0	Further revisions/information added.	James Rayley / Gerard Dickson	02/07/2025